Loading
Showed that oncogene-driven lung cancers respond poorly to immunotherapy and led the pivotal RET and ALK inhibitor studies.
Justin F. Gainor is Director of the Center for Thoracic Cancers at Massachusetts General Hospital Cancer Center. He is known for showing that oncogene-driven lung cancers respond poorly to immunotherapy and for leading the pivotal RET and ALK inhibitor studies, including the ARROW trial of pralsetinib and key analyses of ALK resistance. His selected papers report pralsetinib for RET fusion-positive non-small-cell lung cancer and the low response rates to PD-1 pathway blockade in EGFR-mutant and ALK-rearranged lung cancer. He now directs thoracic cancers at MGH, with continued work on lorlatinib and RET-directed therapy.
| Title | Journal | Year |
|---|---|---|
| Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW) | Lancet Oncology | 2021 |
| EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer | Clinical Cancer Research | 2016 |
Shares RET fusion-positive non-small-cell lung cancer, RET, Non-small-cell lung cancer.
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.
Shares Lorlatinib, ALK-positive non-small-cell lung cancer, ALK, Non-small-cell lung cancer.
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer, RET, Non-small-cell lung cancer.
Shares Lorlatinib, ALK-positive non-small-cell lung cancer, ALK, Non-small-cell lung cancer.
Shares Lorlatinib, ALK-positive non-small-cell lung cancer, ALK, Non-small-cell lung cancer.
Shares Lorlatinib, RET, ALK, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, ALK, Non-small-cell lung cancer.